EsPhALL 2004 An Open-label, Randomized Phase II/III Study to Compare the Safety and Efficacy of Imatinib With Chemotherapy in Pediatric Patients With Ph+ / BCR-ABL+ Acute Lymphoblastic Leukemia (Ph+ALL) - EsPhALL 2004

Trial Profile

EsPhALL 2004 An Open-label, Randomized Phase II/III Study to Compare the Safety and Efficacy of Imatinib With Chemotherapy in Pediatric Patients With Ph+ / BCR-ABL+ Acute Lymphoblastic Leukemia (Ph+ALL) - EsPhALL 2004

Recruiting
Phase of Trial: Phase II/III

Latest Information Update: 15 Sep 2016

At a glance

  • Drugs Imatinib (Primary)
  • Indications Acute lymphoblastic leukaemia
  • Focus Therapeutic Use
  • Acronyms EsPhALL 2004
  • Most Recent Events

    • 15 Sep 2016 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top